Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nupam Mahajan
Washington University, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
TechnoGenesys
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Based on Washington University’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, Washington University determined Dr. Mahajan’s personal financial relationship with TechnoGenesys related to the above referenced research creates a financial conflict of interest due to the following reasons:
• Dr. Mahajan’s personal financial relationship is directly related to the research because this study is evaluating a technology licensed by TechnoGenesys.
• Because Dr. Mahajan owns equity in the company, he could directly benefit should the company’s equity value increase as a result of the study.
• Because Dr. Mahajan will earn royalties from the sale and distribution of the licensed technology, he could directly benefit, should the study impact the value of the intellectual property.
• Dr. Mahajan’s role, as described below, could directly affect the study.
While the committee determined financial conflicts of interest exist, they concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research, based on the following reasons:
• The research is basic in nature and in its early stages.
• Dr. Mahajan is uniquely qualified by virtue of his expertise and experience, and the research could not be conducted as safely or effectively without his involvement.
• Additionally, a plan has been developed to mitigate the financial conflict of interest.
Molecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic Strategies
We have discovered a novel signaling loop, wherein AR protein coordinates with the kinase ACK1 and facilitates modification of histone H4 leading to AR transcriptional activation. AR upon acetylation regulates ACK1 expression. To achieve therapeutic benefit from this new signaling event, we generated a novel ACK1 small molecule inhibitor (R)-9bMS that not only inhibits ACK1 activity and AR expression but also suppresses CRPC tumor growth in mice. In this proposal, we will perform detailed drug development, mechanistic, and preclinical therapeutic studies necessary to credential this treatment approach, with the long-term goal of ultimately advancing this therapy to the clinic.
Filed on March 27, 2019.
Tell us what you know about Nupam Mahajan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Nupam Mahajan filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nupam Mahajan | H. Lee Moffitt Cancer Ctr & Res Inst | Conflict of Interest | TechnoGenesys, Inc. | $0 - $4,999 |
| Nupam Mahajan | Washington University | Conflict of Interest | TechnoGenesys | Value cannot be readily determined |
| Nupam Mahajan | Washington University | Conflict of Interest | TechnoGenesys | Value cannot be readily determined |
| Nupam Mahajan | Washington University | Conflict of Interest | TechnoGenesys | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.